On Tuesday, November, 17th 2011, the Kimmel Cancer Center at Jefferson held the Third Annual Men’s Event benefiting prostate cancer research and patient care at the Prime Rib Restaurant in Philadelphia. The Men’s Event was emceed by Philadelphia Eagles Longsnapper, motivational speaker and magician, Jon Dorenbos. Receiving the Symbol of Courage was John Beuhler, prostate …

Brachytherapy for high-risk prostate cancers patients has historically been considered a less effective modality, but a new study from radiation oncologists at the Kimmel Cancer Center at Jefferson suggests otherwise. A population-based analysis looking at almost 13,000 cases revealed that men who received brachytherapy alone or in combination with external beam radiation therapy (EBRT) had …

Jefferson’s Kimmel Cancer Center has started a Phase I clinical trial investigating the latest prostate cancer chemotherapy drug to extend survival, Cabazitaxel, in combination with radiation and hormone therapy. This first-of-its-kind multimodality approach could improve disease control and eventually survival for locally advanced prostate cancer patients. The single-center, open-label, non-randomized Phase I study of weekly Cabazitaxel …

Ulrich Rodeck, M.D., Ph.D., a professor in the Department of Dermatology and Cutaneous Biology, at Jefferson Medical College, Thomas Jefferson University, received the Ben Franklin-Prostate Cancer Foundation Creativity award for his work in improving the therapeutic window of radiation therapy for prostate cancer. Radiation therapy of locally advanced prostate cancer is associated with severe toxicity …

From October forward, the Kimmel Cancer Center at Jefferson (KCC), a National Cancer Institute-designated cancer center, is celebrating 20 years of service to the community and the groundbreaking cancer research from the scientists and physicians who’ve provided an invaluable contribution to medical science and healthcare. “This is truly a milestone for the Kimmel Cancer Center—it’s …

Radiation oncologist Robert B. Den, M.D., recently joined Thomas Jefferson University Hospital as an attending physician, and was also named an assistant professor at Jefferson Medical College of Thomas Jefferson University in the Department of Radiation Oncology. Dr. Den is a clinical scientist who specializes in the treatment of prostate cancer, combining his laboratory research …

Receiving radiation therapy immediately after a radical prostatectomy is a cost-effective treatment for prostate cancer patients when compared with waiting and acting on elevated prostate-specific antigen (PSA) levels, according to a new study by researchers at Thomas Jefferson University and Hospital. What’s more, a separate, but related study, found that urologists were less likely than …

See the Award Announcement for more information about the Award and its latest recipient. The following was abstracted from the announcement. Dr. Karen Knudsen of the Kimmel Cancer Center received the Ron Ross Award at the 5th Pacific Rim Breast and Prostate Cancer Meeting, held in Kingscliff, Australia, May 3-7, 2011. Dr. Ron Ross was …

Researchers at the Kimmel Cancer Center at Jefferson have shed new light on the longstanding conundrum about what makes a tumor grow—and how to make it stop.  Interestingly, cancer cells accelerate the aging of nearby connective tissue cells to cause inflammation, which ultimately provides “fuel” for the tumor to grow and even metastasize. This revealing …

A widely-available yet expensive radiotherapy technique used to treat prostate cancer patients after surgery has promising benefits—higher dose and less damage to the rectum and bladder—compared to a less precise technique, Thomas Jefferson University researchers document for the first time in a new study published in Practical Radiation Oncology. A team of radiation oncologists and …

Researchers from the Kimmel Cancer Center at Jefferson and two other institutions have discovered new evidence that suggests the “longevity” protein SIRT1, known for its life-spanning effects in different species, can inhibit the development of a known precursor to prostate cancer, prostatic intraepithelial neoplasia (PIN). “Prostate cancer is one of the malignancies that has a …

Dr. Leonard G. Gomella, chair of the Department of Urology and director of Clinical Affairs at the Kimmel Cancer Center at Jefferson, co-chaired the American Society of Clinical Oncology (ASCO) 2011 Genitourinary (GU) Cancers Symposium meeting in Orlando on Feb. 17 though Feb. 19. The “2011 Genitourinary Cancers Symposium: An Evidence-based Multidisciplinary Approach,” was a …

Researchers from Jefferson’s Kimmel Cancer Center have genetic evidence suggesting the antioxidant drugs currently used to treat lung disease, malaria and even the common cold can also help prevent and treat cancers because they fight against mitochondrial oxidative stress—a culprit in driving tumor growth. For the first time, the researchers show that loss of the …

On Tuesday, November, 16th 2010, the Kimmel Cancer Center at Jefferson held the Second Annual Men’s Event at the Prime Rib Restaurant in Philadelphia. The Men’s Event was emceed by Comedian Joe Piscopo. The inaugural Kimmel Cancer Center Men’s Event “Man of the Year Award”  was awarded to Mr. Kenneth Gamble, a world-renowned Grammy winning …

Their study, the first to uncover a new role for this powerful gene, may lead to clinical “barcoding” of a patient’s prostate cancer to help direct therapy (PHILADELPHIA) – The retinoblastoma tumor suppressor gene (Rb), long thought to protect cells against cancer development, appears to play a very different role in prostate cancer, say scientists …

The Ramblewood  Country Club in Mount Laurel, NJ hosted John Runyan’s 2010 “Score For The Cure” Golf Tournament on September 21st 2010. The proceeds benefited the Kimmel Cancer Center of Jefferson. Dietz & Watson was the Title Sponsor of the event. This  marks the 6th year of the event which has raised nearly $1,000,000 in …

The Ace Club will host the Prostate Cancer Foundation’s 8th Annual Philadelphia Prostate Cancer Fundraiser. Clay Hamlin and Neal Rodin invite you to join Michael Milken at the 8th Annual Philadelphia Prostate Cancer Fundraiser.

The Kimmel Cancer Center at Jefferson and Prostate Health International’s Gary Papa Run are offering free prostate screenings as part of a research program. Prostate cancer is the second leading cause of cancer death among men. Screening is important because prostate cancer shows no symptoms in its earliest stages.

Researchers from the Kimmel Cancer Center at Jefferson have found that Stat5, a signaling protein previously found to be key to survival of prostate cancer, is also involved in metastasis. Their study, published in the online edition of Endocrine-Related Cancer, demonstrates in both laboratory and animal models that nuclear Stat5 over-expression leads to a deadly …

Researchers at the Kimmel Cancer Center at Jefferson have discovered how a powerful tumor suppressor called DACH1 works – a finding that explains why restoring its lost function in cancer cells pushes them to become normal again. In the March 29 online early edition of the Proceedings of the National Academy of Sciences (PNAS), the …

Dr. Leonard G. Gomella and colleagues conducted a landmark international randomized, double-blind, placebo-controlled, parallel-group multi-center clinical trial to determine whether dutasteride reduces the risk of incident prostate cancer, as detected on biopsy, among men who are at increased risk for the disease. Over the course of the 4-year study period, dutasteride reduced the risk of …

Karen Knudsen, PhD, Associate Professor, Department of Cancer Biology and Urology at the Kimmel Cancer Center received the Richard E. Weitzman Memorial Award from the Endocrine Society. This annual Laureate Awards annual award recognizes an exceptionally promising young clinical or basic investigator. Knudsen is recognized for scientific achievements in the study of androgen action in …

The Endocrine Society is pleased to announce the 2009 Laureate Awards established in 1944 to recognize the highest achievements in endocrinology including: science, leadership, teaching and service. This year’s Laureate Awards were presented at ENDO 09, the 91st Annual Meeting of The Endocrine Society, being held June 10-13, in Washington, DC. Karen Knudsen, PhD, Associate …

The same biomarker was previously identified as a prognostic factor for breast cancer The absence of a stromal protein called caveolin-1 appears to be a marker for advanced prostate cancer and metastasis, researchers from the Kimmel Cancer Center at Jefferson and Harvard Medical School reported in Cell Cycle. There was an abundance of stromal caveolin-1 …

The Seventh Annual Run 4 Your Life Run/Walk and 1 Mile Fun Walk to benefit Prostate Cancer Research and Awareness will be happening this year on June 21st. Jefferson/KCC already have a team setup but have a long way to go to reach our goal of $1000. The standard registration fee is $25, but if …

Researchers from Thomas Jefferson University have identified a protein that appears to play a significant role in the growth and migration of prostate cancer cells, especially androgen-independent prostate cancer cells. The study was published in the American Journal of Pathology. They also found that prostate cancer cells express more of the protein when compared to …

Researchers at the Kimmel Cancer Center at Jefferson in Philadelphia have shown that by blocking a signaling protein, they can prevent prostate cancer cells from metastatic dissemination. The work opens the door to future studies examining the protein as a target for therapies aimed at keeping prostate cancer at bay. In a series of experiments …

Using a special ultrasound technique to spot areas of blood flow in the prostate gland may substantially reduce the number of unnecessary biopsies, according to a new study by urologists and radiologists at the Jefferson Prostate Diagnostic Center and the Kimmel Cancer Center at Jefferson in Philadelphia. The researchers found that biopsies targeted to areas …

Researchers at Jefferson’s Kimmel Cancer Center in Philadelphia have shown that they can effectively kill prostate cancer cells in both the laboratory and in experimental animal models by blocking a signaling protein that is key to the cancer’s growth. The work proves that the protein, Stat5, is both vital to prostate cancer cell maintenance and …

Scientists at Jefferson’s Kimmel Cancer Center in Philadelphia have found that a signaling protein that is key to prostate cancer cell growth is turned on in nearly all recurrent prostate cancers that are resistant to hormone therapy. If the findings hold up, the protein, called Stat5, may be a specific drug target against an extremely …